NasdaqGM:MIRMBiotechs
Mirum Pharmaceuticals (MIRM) Posts Huge US$790 Million Loss Challenging Bullish Profitability Narrative
Mirum Pharmaceuticals (MIRM) just posted Q1 2026 results with revenue of US$159.9 million, a basic EPS loss of US$13.43 and net income loss excluding extra items of US$790.2 million. The company has reported quarterly revenue of US$99.4 million in Q4 2024, US$111.6 million in Q1 2025, US$127.8 million in Q2 2025, US$133.0 million in Q3 2025 and US$148.9 million in Q4 2025, while EPS over those periods ranged between a loss of US$0.50 and a profit of US$0.06. For investors, a key focus this...